OVERVIEW
Happy Saturday
Welcome to the Stocks Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list -1.73%underperformed the S&P 500 index 0.08%.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list -1.68%underperformed the Nasdaq 100 index -0.21%.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list -2.99% underperformed the Russell 2000 index -1.83%
Top Dawg Of The Week
The Top 25 list's Top Dawg was Cogent Biosciences, which rallied 126% after reporting earnings this week, and getting an analyst upgrade.
Cogent Biosciences Recap
It started out with good news at the end of last week, after unveiling positive clinical data for its investigational treatment bezuclastinib. The trial showed significant improvements in symptom scores and biomarker reductions, positioning the drug for potential FDA submission by late 2025.
Then later this Week:
Shares hit a new 52‑week high at $32.79, up from $14.82 prior close.
Market cap surged to $3.94B, with stock up 133.5% this week and 330% YTD.
Reported EPS: ($0.50) loss, but stronger than expected.
Analyst sentiment: Consensus “Moderate Buy” with $20.83 avg target, according to MarketBeat:
JPMorgan: raised target to $44 (Overweight).
Raymond James: Strong Buy.
Stifel Nicolaus: upgraded to Buy, target $40.
Robert W. Baird: boosted target to $34, Neutral.
Guggenheim: raised target to $20, Buy.
Weiss Ratings: Sell (e+).
COGT is spending lots of cash, as per Fiscal.ai